EMA Recommends Granting a Marketing Authorisation for Nirogacestat By Ogkologos - July 3, 2025 281 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of adult patients with progressing desmoid tumours Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR Tovorafenib Approved for Some Children with Low-Grade Glioma May 28, 2024 ΝΕΥΡΟΕΝΔΟΚΡΙΝΕΙΣ ΟΓΚΟΙ (ΝΕΤS) February 7, 2019 Identification of Actionable Molecular Alterations in NCI-MATCH November 2, 2020 Phlebotomist Breaks Into Ballet Performance In The Middle Of The Hospital September 16, 2021 Load more HOT NEWS RNF43 Mutations Warrant Further Validation for Potential to Prioritise Anti-EGFR/BRAF Combinations... Adding Avelumab to Preoperative Chemoradiotherapy Provides Promising Anti-Tumour Activity in Locally... New on NCI’s Websites, March 2020 Induction ICI Combination Followed by CRT Is An Effective Bladder-Sparing Treatment...
